NCT05168163 - Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | Biotech Hunter

Enrollment

122

Participants

Timeline

Start Date

May 27, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Locally Advanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8Unresectable Hepatocellular Carcinoma

Interventions

BIOLOGICAL

Atezolizumab

Given IV

DRUG

Cabozantinib

Given PO

DRUG

Lenvatinib

Given PO

Trial Locations (16)

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

15212

RECRUITING

Allegheny General Hospital, Pittsburgh

27710

COMPLETED

Duke University Medical Center, Durham

33331

WITHDRAWN

Cleveland Clinic Weston Florida, Weston

44106

WITHDRAWN

University Hospitals Cleveland Medical Center, Cleveland

48106

RECRUITING

Michigan Cancer Research Consortium NCORP, Ann Arbor

48109

NOT_YET_RECRUITING

University of Michigan Comprehensive Cancer Center, Ann Arbor

53226

RECRUITING

Froedtert and the Medical College of Wisconsin LAPS, Milwaukee

RECRUITING

Medical College of Wisconsin, Milwaukee

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

57701

RECRUITING

Rapid City Regional Hospital, Rapid City

60637

NOT_YET_RECRUITING

University of Chicago Comprehensive Cancer Center, Chicago

61801

RECRUITING

Carle Cancer Center NCI Community Oncology Research Program, Urbana

70112

RECRUITING

University Medical Center New Orleans, New Orleans

85259

RECRUITING

Mayo Clinic in Arizona, Scottsdale

32224-9980

WITHDRAWN

Mayo Clinic in Florida, Jacksonville